Related Experiment Video

Updated: Jul 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

393

Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of

Victor M Rivera-Francia1, Virgilio E Failoc-Rojas1,2, Robert Villacorta-Carranza1

  • 1ALIADA Centro Oncológico, Lima, Peru.

Leukemia & Lymphoma
|October 5, 2023
PubMed

Insights

Pembrolizumab offers a promising treatment for relapsed or refractory Natural Killer/T-cell Lymphoma (NK/T-cellL). This immunotherapy shows high response rates and good survival outcomes, regardless of PD-L1 expression.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematologic Malignancies

Background:

  • Natural Killer/T-cell Lymphoma (NK/T-cellL) is an aggressive non-Hodgkin's lymphoma with limited therapeutic options for relapsed or refractory disease.
  • Patients with advanced NK/T-cellL often face poor prognoses after standard second-line treatments.

Approach:

  • A systematic review was conducted following MOSE guidelines, searching major databases (PubMed/MEDLINE, EMBASE, Scopus).
  • Fourteen articles evaluating anti-PD-1 therapy, specifically pembrolizumab, in NK/T-cellL patients were analyzed.

Key Points:

  • Pembrolizumab demonstrated an objective response rate of 84.50% in patients with refractory/recurrent NK/T-cellL.
  • Complete response rates reached 61.6%, with disease-free survival varying from 2 to 48 months.
  • Study quality varied, with case reports showing moderate to high bias and clinical trials exhibiting high bias.

Conclusions:

  • Pembrolizumab represents a viable treatment option for refractory/recurrent NK/T-cellL, irrespective of PD-L1 expression.
  • Anti-PD-1 therapies show favorable short- and long-term efficacy with a manageable safety profile in this patient population.
Keywords:
LymphomaNK-T-cellimmune checkpoint inhibitors (DeCS-BIREME)programmed cell death 1 receptor

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K